Testicular cancer in Europe and the USA: Survival still rising among older patients

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 508-513

  Verhoeven, R H A ^a   Gondos, Adam ^b   Janssen heijnen, M L G ^a,c   Saum, K U ^b   Brewster, D H ^d,p   Holleczek, Bernd ^e   Crocetti, Emanuele ^f   Rosso, Stefano ^g   Hakulinen, Timo ^h   Aareleid, T ⁱ   Brenner, Hermann ^b   Aareleid, Tiiu ⁱ   Bray, Freddie ^j   Coebergh, Jan Willem ^a   Janssen Heijnen, Maryska ^a   Mägi, Margit ^k   Rachtan, Jadwiga ^l   Smailyte, Giedre ^m   Usel, Massimo ⁿ   Žakelj, Maja Primic ^o  

^a Eindhoven Cancer Registry   (Netherlands)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c VIECURI MEDICAL CENTER   (Netherlands)

^d INFORMATION SERVICES DIVISION   (United Kingdom)

^e SAARLAND CANCER REGISTRY   (Germany)

^f Florence Cancer Registry   (Italy)

^g CPO Centre for Epidemiology and Prevention in Oncology in Piedmont   (Italy)

^h FINNISH CANCER REGISTRY   (Finland)

ⁱ NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^j CANCER REGISTRY OF NORWAY   (Norway)

^k Estonian Cancer Registry   (Estonia)

^l Cracow Cancer Registry   (Poland)

^m Lithuanian Cancer Registry   (Lithuania)

ⁿ GENEVA CANCER REGISTRY   (Switzerland)

^o INSTITUTE OF ONCOLOGY   (Slovenia)

^p Scottish Cancer Registry   (United Kingdom)

more..

Author keywords

Cancer registries; Nonseminomas; Population based; Relative survival; Seminomas; Testicular cancer

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEMINOMA; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; TESTIS NONSEMINOMA CANCER; UNITED STATES;

EID: 84873845778     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds460     Document Type: Article

References (31)

1. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002; 99: 4592-4595.
2. Sant M, Allemani C, Santaquilani M et al EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931-991.
3. Bray F, Ferlay J, Devesa SS et al Interpreting the international trends in testicular seminoma and nonseminoma incidence. Nat Clin Pract Urol 2006; 3: 532-543.
4. McGlynn KA, Cook MB. Etiologic factors in testicular germ-cell tumors. Future Oncol 2009; 5: 1389-1402.
5. Stang A, Rusner C, Eisinger B et al Subtype-specific incidence of testicular cancer in Germany: a pooled analysis of nine population-based cancer registries. Int J Androl 2009; 32: 306-316.
6. Albers P, Albrecht W, Algaba F et al EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60: 304-319.
7. Verhoeven RH, Coebergh JW, Kiemeney LA et al Testicular cancer: trends in mortality are well explained by changes in treatment and survival in the southern Netherlands since 1970. Eur J Cancer 2007; 43: 2553-2558.
8. Biggs ML, Schwartz SM. Chapter 21, Cancer of the Testis. In Ries LAM, Young JL, Keel GE et al (eds), SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program 2007;165-170.
9. Spermon JR, Witjes JA, Kiemeney LA. Difference in stage and morphologyadjusted survival between young and elderly patients with a testicular germ cell tumor. Urology 2002; 60: 889-893.
10. Sant M, Aareleid T, Artioli ME et al Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer 2007; 43: 585-592.
11. Huyghe E, Muller A, Mieusset R et al Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol 2007; 52: 1710-1716.
12. Gondos A, Bray F, Brewster DH et al Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer 2008; 44: 1463-1475.
13. Surveillance, Epidemiology, and End Results (SEER) Program. Limited-Use Data (1973-2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission; www.seer.cancer.gov.
14. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101-121.
15. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological Note No. 10. End Results Section. Betheseda, MD: National Cancer Institute 1959.
16. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-335.
17. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002; 20: 826-832.
18. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 2002; 31: 456-462.
19. Talbäck M, Stenbeck M, Rosen M. Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer 2004; 40: 1361-1372.
20. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006; 164: 689-696.
21. Brenner H, Hakulinen T. Model based hybrid analysis of cancer patient survival. Eur J Cancer 2007; 43: 921-927.
22. Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 2004; 40: 2494-2501.
23. Gondos A, Bray F, Hakulinen T et al Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009; 20: 564-573.
24. Aareleid T, Gondos A, Brenner H et al Testicular cancer survival in Estonia: improving but still relatively low. Acta Oncol 2011; 50: 99-105.
25. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
26. Sekine I, Fukuda H, Kunitoh H et al Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998; 28: 463-473.
27. O'Sullivan JM, Huddart RA, Norman AR et al Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14: 91-96.
28. Simpson AB, Paul J, Graham J et al Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998; 78: 1061-1066.
29. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev 2005; 31: 380-402.
30. NCCN. NCCN Clinical Practice Guidelines in Oncology, Testicular Cancer. Fort Washington, PA, USA: National Comprehensive Cancer Network, Version 1.2012, www.NCCN.org. 2012.
31. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 1997; 50: 939-945.